Join us for an exclusive Oracle & TD2 dinner

You're Invited!

Date: April 23, 2019

Location:  EVOO (35 Third Street, Cambridge, MA 02142)

Time: 5:30 p.m. hospitality & 6 p.m. dinner


Move Your Drug to Market, Faster

TD2 is a contract research organization (CRO) dedicated to Precision Medicine for Oncology. Translational Drug Development (TD2) and Oracle Health Sciences partner to help innovative biotech and pharma companies to bring cancer treatments to patients as quickly as possible.

Oracle Health Sciences and TD2 are delighted to sponsor a dinner focused on complete phase 1 study design. This exclusive event will take place at EVOO in Cambridge, MA.

A select group of senior level emerging Biopharma executives are invited to discuss designing Oncology studies, with specific emphasis on phase 1 Oncology trials.

As science becomes more personalized in key therapeutic areas, breakthrough life sciences discoveries and innovative treatment approaches are transforming patient care. Emerging drug and device sponsors face multiple challenges implementing these new approaches and methodologies to achieve cost control, timeliness, and efficacy in clinical trials. This event will feature speaker Jennifer Keppler, VP of Translational Medicine from TD2, who will discuss their experience with complete Phase 1 study design.


The usual clinical development plan for a new agent (NA) includes a phase I monotherapy trial. However, because many new agents are eventually developed as part of a combination, additional phase I trials assessing the new agent in combination with a standard agent are usually performed (usually as individual phase Ib studies). Our hypothesis is that within a single protocol, several combination phase I trials could be conducted simultaneously.


Utilizing a complete phase Ib trial design is feasible. Our initial experience has suggested that this approach is safe and highly efficient with several potential advantages over multiple sequential combination phase Ib studies.


The format of this event will be a short presentation after hospitality hour, followed by dinner and interactive discussion. The evening’s conversation will include senior executives from Oracle Health Sciences, TD2 and your peer sponsors.


For more information or to reserve your spot, please contact